In vivo evidence has shown that tumor-associated neutrophils (TANs) can change their function from a pro-tumor phenotype (N2) to an anti-tumor (N1) phenotype with the addition of a TGFβ inhibitor, arguing that TGFβ is an important factor driving the N2 phenotype (10). This evidence concerns the gene TGFB1 and neoplasm.